Concepts (198)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 8 | 2025 | 771 | 2.620 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 5 | 2024 | 628 | 1.950 |
Why?
|
| Bronchoscopy | 4 | 2019 | 174 | 1.180 |
Why?
|
| Anti-Asthmatic Agents | 4 | 2025 | 118 | 1.150 |
Why?
|
| Patient Outcome Assessment | 2 | 2020 | 93 | 1.070 |
Why?
|
| Shock, Septic | 3 | 2025 | 156 | 1.010 |
Why?
|
| Noninvasive Ventilation | 3 | 2019 | 33 | 0.880 |
Why?
|
| Bronchodilator Agents | 1 | 2024 | 150 | 0.780 |
Why?
|
| Betacoronavirus | 3 | 2020 | 300 | 0.780 |
Why?
|
| Positive-Pressure Respiration | 2 | 2019 | 85 | 0.760 |
Why?
|
| Respiration, Artificial | 4 | 2020 | 501 | 0.700 |
Why?
|
| Smoking | 3 | 2022 | 942 | 0.700 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 379 | 0.690 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 390 | 0.680 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2020 | 23 | 0.670 |
Why?
|
| Symptom Flare Up | 1 | 2019 | 24 | 0.640 |
Why?
|
| Hepatitis B, Chronic | 1 | 2021 | 85 | 0.640 |
Why?
|
| Intensive Care Units | 4 | 2019 | 524 | 0.630 |
Why?
|
| Fever | 2 | 2020 | 312 | 0.610 |
Why?
|
| Dengue | 1 | 2020 | 122 | 0.600 |
Why?
|
| Diagnosis, Differential | 3 | 2020 | 1964 | 0.600 |
Why?
|
| Legionellosis | 1 | 2018 | 4 | 0.600 |
Why?
|
| Pneumonia, Mycoplasma | 1 | 2018 | 15 | 0.580 |
Why?
|
| Stroke | 3 | 2023 | 1068 | 0.560 |
Why?
|
| Glomerulonephritis | 1 | 2018 | 74 | 0.560 |
Why?
|
| Fungemia | 1 | 2017 | 23 | 0.550 |
Why?
|
| Lung Neoplasms | 3 | 2019 | 1541 | 0.530 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2018 | 121 | 0.520 |
Why?
|
| Candidiasis | 1 | 2017 | 137 | 0.500 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2016 | 32 | 0.500 |
Why?
|
| Fibrinolytic Agents | 1 | 2018 | 206 | 0.500 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2016 | 22 | 0.490 |
Why?
|
| Inpatients | 1 | 2020 | 553 | 0.490 |
Why?
|
| Postoperative Hemorrhage | 1 | 2016 | 81 | 0.490 |
Why?
|
| HIV Infections | 2 | 2019 | 2063 | 0.480 |
Why?
|
| Pneumothorax | 1 | 2016 | 83 | 0.480 |
Why?
|
| Pulmonary Embolism | 1 | 2018 | 189 | 0.470 |
Why?
|
| Hospital Mortality | 4 | 2025 | 1077 | 0.470 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2017 | 246 | 0.470 |
Why?
|
| Hemorrhage | 2 | 2020 | 517 | 0.470 |
Why?
|
| Esophagitis | 1 | 2015 | 38 | 0.470 |
Why?
|
| Pulmonary Edema | 1 | 2015 | 58 | 0.470 |
Why?
|
| Acute Lung Injury | 1 | 2015 | 68 | 0.460 |
Why?
|
| Shock, Hemorrhagic | 1 | 2015 | 55 | 0.460 |
Why?
|
| Humans | 35 | 2025 | 132373 | 0.450 |
Why?
|
| Sarcoma, Kaposi | 1 | 2016 | 131 | 0.450 |
Why?
|
| Hepatic Encephalopathy | 1 | 2015 | 84 | 0.440 |
Why?
|
| Intracranial Thrombosis | 1 | 2014 | 12 | 0.440 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2017 | 339 | 0.440 |
Why?
|
| Streptococcus agalactiae | 1 | 2015 | 103 | 0.430 |
Why?
|
| Lung Diseases | 1 | 2018 | 409 | 0.430 |
Why?
|
| Factor VIIa | 1 | 2014 | 24 | 0.430 |
Why?
|
| Anti-Bacterial Agents | 2 | 2023 | 2557 | 0.420 |
Why?
|
| Ultrasonography, Doppler | 1 | 2015 | 186 | 0.420 |
Why?
|
| Abscess | 1 | 2015 | 140 | 0.420 |
Why?
|
| Patient Admission | 3 | 2020 | 185 | 0.420 |
Why?
|
| Respiratory Insufficiency | 1 | 2016 | 247 | 0.420 |
Why?
|
| Hemophilia A | 1 | 2014 | 25 | 0.420 |
Why?
|
| Fluid Therapy | 1 | 2014 | 148 | 0.410 |
Why?
|
| Postoperative Complications | 2 | 2016 | 3140 | 0.410 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2014 | 64 | 0.410 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2014 | 64 | 0.410 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2015 | 237 | 0.400 |
Why?
|
| Hematoma | 1 | 2014 | 92 | 0.400 |
Why?
|
| Lung | 3 | 2019 | 1556 | 0.400 |
Why?
|
| Peptide Fragments | 1 | 2017 | 799 | 0.400 |
Why?
|
| Biological Products | 2 | 2025 | 135 | 0.390 |
Why?
|
| Neck | 1 | 2014 | 142 | 0.390 |
Why?
|
| Surgical Wound Infection | 1 | 2015 | 271 | 0.390 |
Why?
|
| Streptococcal Infections | 1 | 2015 | 248 | 0.380 |
Why?
|
| Face | 1 | 2014 | 189 | 0.380 |
Why?
|
| Point-of-Care Systems | 1 | 2015 | 193 | 0.380 |
Why?
|
| Resuscitation | 1 | 2014 | 268 | 0.370 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2021 | 991 | 0.370 |
Why?
|
| Lymph Nodes | 1 | 2014 | 388 | 0.360 |
Why?
|
| Colitis, Ulcerative | 1 | 2014 | 217 | 0.360 |
Why?
|
| Hypertension, Pulmonary | 1 | 2016 | 464 | 0.360 |
Why?
|
| Coronary Artery Bypass | 1 | 2015 | 537 | 0.350 |
Why?
|
| Male | 20 | 2025 | 65072 | 0.350 |
Why?
|
| Liver Neoplasms | 1 | 2021 | 1396 | 0.330 |
Why?
|
| Middle Aged | 14 | 2025 | 28895 | 0.330 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 2062 | 0.330 |
Why?
|
| Aged | 14 | 2025 | 21386 | 0.330 |
Why?
|
| Sepsis | 1 | 2014 | 518 | 0.320 |
Why?
|
| Female | 20 | 2025 | 70809 | 0.300 |
Why?
|
| Liver Cirrhosis | 1 | 2015 | 899 | 0.280 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 764 | 0.280 |
Why?
|
| Biopsy | 3 | 2016 | 1289 | 0.270 |
Why?
|
| Drug Therapy, Combination | 2 | 2024 | 1163 | 0.250 |
Why?
|
| Aged, 80 and over | 6 | 2025 | 7112 | 0.230 |
Why?
|
| Retrospective Studies | 9 | 2025 | 17371 | 0.220 |
Why?
|
| Length of Stay | 3 | 2020 | 1380 | 0.220 |
Why?
|
| Phenotype | 3 | 2023 | 4545 | 0.220 |
Why?
|
| Disease Progression | 2 | 2023 | 2228 | 0.210 |
Why?
|
| Safety-net Providers | 1 | 2025 | 71 | 0.210 |
Why?
|
| New York City | 2 | 2020 | 65 | 0.210 |
Why?
|
| Administration, Inhalation | 1 | 2024 | 190 | 0.210 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 558 | 0.200 |
Why?
|
| Doxycycline | 1 | 2023 | 121 | 0.200 |
Why?
|
| Sputum | 1 | 2023 | 116 | 0.190 |
Why?
|
| Biological Factors | 1 | 2022 | 27 | 0.190 |
Why?
|
| Eosinophils | 1 | 2023 | 122 | 0.190 |
Why?
|
| Health Status Disparities | 1 | 2025 | 251 | 0.190 |
Why?
|
| Respiratory System | 1 | 2022 | 98 | 0.180 |
Why?
|
| May-Thurner Syndrome | 1 | 2021 | 4 | 0.180 |
Why?
|
| Incidence | 2 | 2020 | 3362 | 0.180 |
Why?
|
| Inflammation | 2 | 2023 | 1526 | 0.180 |
Why?
|
| Adult | 8 | 2025 | 31624 | 0.180 |
Why?
|
| Neutrophils | 1 | 2023 | 359 | 0.170 |
Why?
|
| Prognosis | 3 | 2020 | 5010 | 0.170 |
Why?
|
| Gingiva | 1 | 2020 | 11 | 0.170 |
Why?
|
| Healthcare Disparities | 1 | 2025 | 482 | 0.160 |
Why?
|
| Thromboembolism | 1 | 2020 | 90 | 0.160 |
Why?
|
| Pulmonary Atelectasis | 1 | 2019 | 14 | 0.160 |
Why?
|
| Venous Thrombosis | 1 | 2021 | 170 | 0.160 |
Why?
|
| Double-Blind Method | 1 | 2023 | 1649 | 0.160 |
Why?
|
| Conservative Treatment | 1 | 2019 | 42 | 0.150 |
Why?
|
| Travel | 1 | 2020 | 125 | 0.150 |
Why?
|
| Legionella pneumophila | 1 | 2018 | 6 | 0.150 |
Why?
|
| Venous Thromboembolism | 2 | 2020 | 186 | 0.150 |
Why?
|
| Mycoplasma pneumoniae | 1 | 2018 | 13 | 0.150 |
Why?
|
| Pandemics | 3 | 2020 | 1188 | 0.150 |
Why?
|
| Bronchiectasis | 1 | 2018 | 22 | 0.150 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2018 | 30 | 0.140 |
Why?
|
| Radiography, Thoracic | 1 | 2018 | 153 | 0.140 |
Why?
|
| Immunoglobulin M | 1 | 2018 | 216 | 0.140 |
Why?
|
| Lipopeptides | 1 | 2017 | 36 | 0.140 |
Why?
|
| Echinocandins | 1 | 2017 | 44 | 0.140 |
Why?
|
| Pulmonary Alveoli | 1 | 2018 | 141 | 0.140 |
Why?
|
| Survival Analysis | 1 | 2020 | 1570 | 0.130 |
Why?
|
| Coinfection | 1 | 2018 | 189 | 0.130 |
Why?
|
| Glioblastoma | 1 | 2020 | 374 | 0.130 |
Why?
|
| Computed Tomography Angiography | 1 | 2018 | 215 | 0.130 |
Why?
|
| Severity of Illness Index | 2 | 2025 | 3088 | 0.130 |
Why?
|
| Risk Factors | 3 | 2020 | 10912 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 2169 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2020 | 1230 | 0.120 |
Why?
|
| Anticoagulants | 1 | 2020 | 607 | 0.120 |
Why?
|
| Thrombosis | 1 | 2020 | 529 | 0.120 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 2303 | 0.120 |
Why?
|
| Sternum | 1 | 2015 | 53 | 0.110 |
Why?
|
| Antifungal Agents | 1 | 2017 | 313 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 1 | 2018 | 1556 | 0.110 |
Why?
|
| Hospitalization | 2 | 2020 | 1895 | 0.110 |
Why?
|
| Certolizumab Pegol | 1 | 2014 | 8 | 0.110 |
Why?
|
| Tracheostomy | 1 | 2017 | 201 | 0.110 |
Why?
|
| Antigens, Viral | 1 | 2016 | 439 | 0.110 |
Why?
|
| Up-Regulation | 1 | 2017 | 879 | 0.110 |
Why?
|
| Chest Pain | 1 | 2015 | 127 | 0.110 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2014 | 65 | 0.110 |
Why?
|
| Ecchymosis | 1 | 2014 | 12 | 0.110 |
Why?
|
| Facial Pain | 1 | 2014 | 8 | 0.110 |
Why?
|
| Mercaptopurine | 1 | 2014 | 72 | 0.110 |
Why?
|
| Mediastinum | 1 | 2014 | 47 | 0.110 |
Why?
|
| Prednisone | 1 | 2014 | 252 | 0.100 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 2145 | 0.100 |
Why?
|
| Radiography | 1 | 2015 | 818 | 0.100 |
Why?
|
| Cerebral Hemorrhage | 1 | 2014 | 158 | 0.100 |
Why?
|
| Polyethylene Glycols | 1 | 2014 | 251 | 0.100 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 304 | 0.090 |
Why?
|
| Biomarkers | 2 | 2020 | 3391 | 0.090 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 74 | 0.080 |
Why?
|
| Echocardiography | 1 | 2016 | 1125 | 0.080 |
Why?
|
| Brain Neoplasms | 1 | 2020 | 1409 | 0.080 |
Why?
|
| Treatment Outcome | 3 | 2024 | 13020 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2015 | 988 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 672 | 0.080 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 1285 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2016 | 3422 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2020 | 3853 | 0.070 |
Why?
|
| Hospitals, Community | 2 | 2020 | 55 | 0.060 |
Why?
|
| United States | 3 | 2025 | 11631 | 0.060 |
Why?
|
| Iliac Vein | 1 | 2021 | 29 | 0.040 |
Why?
|
| Femoral Vein | 1 | 2021 | 48 | 0.040 |
Why?
|
| Iliac Artery | 1 | 2021 | 75 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 39 | 0.040 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2020 | 67 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 2020 | 99 | 0.040 |
Why?
|
| Comorbidity | 1 | 2025 | 1605 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2020 | 242 | 0.040 |
Why?
|
| Cytokines | 1 | 2024 | 1368 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 263 | 0.040 |
Why?
|
| Health Status | 1 | 2020 | 409 | 0.040 |
Why?
|
| Cerebellum | 1 | 2020 | 463 | 0.030 |
Why?
|
| Texas | 1 | 2025 | 3629 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2025 | 5153 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 2930 | 0.030 |
Why?
|
| APACHE | 1 | 2011 | 50 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2020 | 3710 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 440 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 585 | 0.020 |
Why?
|
| Vitamin D | 1 | 2011 | 180 | 0.020 |
Why?
|
| ROC Curve | 1 | 2011 | 598 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 1009 | 0.020 |
Why?
|
| Renal Insufficiency | 1 | 2011 | 253 | 0.020 |
Why?
|
| Time Factors | 1 | 2019 | 6457 | 0.020 |
Why?
|
| Logistic Models | 1 | 2011 | 1840 | 0.020 |
Why?
|
| Calcium | 1 | 2011 | 1083 | 0.020 |
Why?
|